Lir Life Sciences Unveils Positive Interim Results for Needle-Free GLP-1 Patch in Obesity Therapy Trial
I'm PortAI, I can summarize articles.
LIR Life Sciences Corp. has reported positive interim results from its trial of a needle-free GLP-1 patch for obesity therapy. The study showed that the CPP-Semaglutide formulation significantly lowered blood glucose levels in a standard model. These results are crucial for refining the formulation and confirming dosing parameters for future studies. The company aims to develop scalable and affordable obesity treatments using innovative drug delivery methods, including transdermal patches and oral formulations.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments